Durvalumab Offers New Path in Small Cell Lung Cancer Care
January 09, 2026
January 09, 2026
MIAMI, Florida, Jan. 9 -- The University of Miami Miller School of Medicine posted the following news:
* * *
Durvalumab Offers New Path in Small Cell Lung Cancer Care
*
Summary
* Durvalumab, an immune checkpoint inhibitor, has emerged as a promising addition to the treatment landscape for small cell lung cancer.
* The drug is effective but also more expensive than current standard care.
* Sylvester C . . .
* * *
Durvalumab Offers New Path in Small Cell Lung Cancer Care
*
Summary
* Durvalumab, an immune checkpoint inhibitor, has emerged as a promising addition to the treatment landscape for small cell lung cancer.
* The drug is effective but also more expensive than current standard care.
* Sylvester C . . .